Mon, Jul 28, 2014, 1:40 AM EDT - U.S. Markets open in 7 hrs 50 mins


% | $
Click the to save as a favorite.

Medivation, Inc. (MDVN) Message Board

  • dumontlaw dumontlaw Apr 5, 2013 3:10 PM Flag

    Radium 223 from Bayer is the 6th similar drug

    that offers a 30% improvement from the spread of prostate cancer to the bones. This field is too crowded and too expensive.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Another new voice - probably someone who bought a few puts when the stock seemed to be showing weakness - pipes up from the wilderness with a piece of half-digested misinformation. Radium-233, which is probably a helpful drug for those in the final stages of mCRPC, will have no impact whatsoever on the prospects for Xtandi. As for the field being "crowded", you are wrong. There are no viable alternatives to Xtandi, other than Zytiga, which is a less desirable drug on a couple of counts. As for "expensive", you're right. All of these drugs are very expensive. But when you're dying and an insurance company or Medicare is picking up virtually all of the cost, this is unimportant. (At least in the US. The Europeans have a somewhat more cost-conscious approach to these issues.)

75.79+0.33(+0.44%)Jul 25 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.